OncoMatch/Clinical Trials/NCT06066203
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Is NCT06066203 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GNC-035 for non-hodgkin's lymphoma.
Treatment: GNC-035 — Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to determine RP2D. Phase II Main objective: To explore the efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
Patients who have failed at least one line of standard therapy
Cannot have received: major surgery
Patients who have undergone major surgery within 28 days prior to the administration of this study or are scheduled for major surgery during the study period
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 weeks before initiating GNC-035 treatment
Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-035 treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
Cannot have received: radiotherapy
Exception: within 4 weeks before initiating GNC-035 treatment
Radiotherapy or macromolecular targeted therapy within 4 weeks before initiating GNC-035 treatment
Cannot have received: macromolecular targeted therapy
Exception: within 4 weeks before initiating GNC-035 treatment
Radiotherapy or macromolecular targeted therapy within 4 weeks before initiating GNC-035 treatment
Cannot have received: chemotherapy
Exception: within 2 weeks or 5 half-lives (whichever is shorter) before treatment
chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives (whichever is shorter) before treatment
Cannot have received: small-molecule targeted therapy
Exception: within 2 weeks or 5 half-lives (whichever is shorter) before treatment
chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives (whichever is shorter) before treatment
Cannot have received: anti-CD20 therapy
Exception: within 4 weeks before initiating GNC-035 treatment with ongoing response
Anti-CD20 or anti-CD79b treatment within 4 weeks before initiating GNC-035 treatment with ongoing response
Cannot have received: anti-CD79b therapy
Exception: within 4 weeks before initiating GNC-035 treatment with ongoing response
Anti-CD20 or anti-CD79b treatment within 4 weeks before initiating GNC-035 treatment with ongoing response
Cannot have received: CAR-T cell therapy
Exception: within 12 weeks before initiating GNC-035 treatment
CAR-T therapy within 12 weeks before initiating GNC-035 treatment
Cannot have received: investigational drug
Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the administration of this study
Use of investigational drugs from other clinical trials within 4 weeks or 5 half-lives (whichever is shorter) before the administration of this study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify